{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.fortrea.com/insights/progressive-myopia-treatment-evaluation-multifocal-contact-trial#webpage",
"url": "https://www.fortrea.com/insights/progressive-myopia-treatment-evaluation-multifocal-contact-trial",
"name": "Progressive myopia treatment evaluation in a multifocal contact trial",
"description": "This Fortrea case study highlights the evaluation of a multifocal contact lens as a treatment approach for progressive myopia in children through a multinational ophthalmic medical device clinical trial. Progressive myopia is a worsening form of shortsightedness that often begins during childhood and can lead to increasing visual impairment over time, with particularly high prevalence among Asian populations. The study enrolled myopic children aged 7 to under 13 years across Canada, Hong Kong, Singapore, and the United States, while also addressing future regulatory considerations that required at least 30% of enrolled participants to be native Chinese. Delivering the trial required expertise in pediatric patient recruitment, ophthalmology research, medical device development, diversity planning, and multinational regulatory strategy. Through coordinated global study execution, recruitment planning, and operational management, Fortrea supported the evaluation of a multifocal contact lens intervention while navigating the complexities associated with pediatric ophthalmology trials, demographic enrollment requirements, and international medical device development programs."
},
{
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://www.fortrea.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Insights",
"item": "https://www.fortrea.com/insights/"
},
{
"@type": "ListItem",
"position": 3,
"name": "Progressive myopia treatment evaluation in a multifocal contact trial",
"item": "https://www.fortrea.com/insights/progressive-myopia-treatment-evaluation-multifocal-contact-trial"
}
]
},
{
"@type": "Organization",
"@id": "https://www.fortrea.com/#organization",
"name": "Fortrea",
"url": "https://www.fortrea.com",
"description": "Fortrea is a global contract research organization built on more than 30 years of experience and one of the earliest CRO legacies in the industry—as Covance, evolving within Labcorp, and now operating as Fortrea. With deep expertise across Phase I–IV clinical trials, Fortrea advances clinical research through a patient-centric approach that prioritizes meaningful outcomes, stronger site–CRO relationships, and operational excellence. Fortrea partners with biopharmaceutical, biotech, and medical device companies to advance therapies through every stage of clinical development. This commitment is further reinforced by the launch of Fortrea Intelligent Technology, enabling smarter, more connected, and data-driven clinical development. Through Fortrea Intelligent Technology, the organization is advancing data-driven, technology-enabled clinical development to improve speed, quality, and patient outcomes. It is shaped by experience, innovation, and a commitment to raising standards in clinical research—focused on accelerating development and helping bring life-changing treatments to patients around the world.",
"logo": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png",
"sameAs": [
"https://www.linkedin.com/company/fortrea",
"https://www.threads.net/@fortreacro",
"https://twitter.com/fortrea",
"https://www.youtube.com/@Fortrea/",
"https://www.facebook.com/Fortrea-104143099267108",
"https://www.instagram.com/fortreacro"
]
},
{
"@type": "Article",
"@id": "https://www.fortrea.com/insights/progressive-myopia-treatment-evaluation-multifocal-contact-trial#casestudy",
"mainEntityOfPage": {
"@id": "https://www.fortrea.com/insights/progressive-myopia-treatment-evaluation-multifocal-contact-trial#webpage"
},
"headline": "Progressive Myopia Treatment Evaluation: Delivering a Pediatric Multifocal Contact Lens Trial Across Global Ophthalmology Sites | Fortrea Case Study",
"description": "This Fortrea case study highlights the evaluation of a multifocal contact lens as a treatment approach for progressive myopia in children through a multinational ophthalmic medical device clinical trial. Progressive myopia is a worsening form of shortsightedness that often begins during childhood and can lead to increasing visual impairment over time, with particularly high prevalence among Asian populations. The study enrolled myopic children aged 7 to under 13 years across Canada, Hong Kong, Singapore, and the United States, while also addressing future regulatory considerations that required at least 30% of enrolled participants to be native Chinese. Delivering the trial required expertise in pediatric patient recruitment, ophthalmology research, medical device development, diversity planning, and multinational regulatory strategy. Through coordinated global study execution, recruitment planning, and operational management, Fortrea supported the evaluation of a multifocal contact lens intervention while navigating the complexities associated with pediatric ophthalmology trials, demographic enrollment requirements, and international medical device development programs.",
"genre": "Case Study",
"image": {
"@type": "ImageObject",
"url": "https://www.fortrea.com/sites/default/files/2026-03/yopia-treatment-evaluation-multifocal-trial.jpg"
},
"author": {
"@type": "Organization",
"name": "Fortrea",
"url": "https://www.fortrea.com/"
},
"publisher": {
"@id": "https://www.fortrea.com/#organization"
},
"datePublished": "2026-03-18",
"dateModified": "2026-03-18",
"encoding": {
"@type": "MediaObject",
"contentUrl": "https://www.fortrea.com/sites/default/files/2026-03/myopia-treatment-multifocal-lens-trial.pdf",
"encodingFormat": "application/pdf"
}
}
]
}